Nobivac^® Canine 1-DAPPv+L₄

Pharmaceutical Name

Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus. Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin.

Features & Benefits

• High-titer, low-passage parvovirus vaccine. 
  
• Contains canine parvovirus type 2b, the most prevalent field strain of parvovirus. 
  
• Parvo fraction overrides maternal antibodies in young puppies. 
  
• Shows no reversion to virulence. 
  
• Contains Onderstepoort-type strain of canine distemper virus, proven efficacious for more than 50 years. 
  
• L. canicola, L. grippotyphosa, L. icterohaemorrhagiae, and L. pomona components provide convenient, broad protection against leptospirosis.
• 
  
• Nobivac Canine 1-DAPPv+L₄ is a modified live virus vaccine for the vaccination of healthy dogs as an aid in the prevention of disease caused by canine distemper virus, adenovirus type 2 (hepatitis), canine parainfluenza virus, and canine parvovirus. It is also indicated as an aid in the prevention of disease and mortality caused by L. canicola, L. icterohaemorrhagiae, L. pomona, and L. grippotyphosa. Data indicates that corneal opacity is not associated with the use of this product.